---
layout: post
title: "Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:37 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05178
original_published: 2024-03-12 00:00:00 +0000
significance: 8.00
---

# Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 12, 2024 00:00 UTC
**Document Number:** 2024-05178

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Early Alzheimer's Disease: Developing Drugs for Treatment." This draft guidance is intended to assist sponsors in the clinical development of drugs for the treatment of the stages of sporadic Alzheimer's disease (AD) that occur before the onset of overt dementia. This draft guidance revises the previous draft guidance for industry of the same name issued on February 16, 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/12/2024-05178/early-alzheimers-disease-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2024-05178

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
